The Solute Carrier Family 12 Member 2 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 12 Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Solute Carrier Family 12 Member 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, and Cardiovascular which include the indications Autism Spectrum Disorder (ASD), Epilepsy, Down Syndrome, Fragile X Syndrome, and Ischemic Stroke. It also reviews key players involved in Solute Carrier Family 12 Member 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Solute Carrier Family 12 Member 2 pipeline targets constitutes close to nine molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 3, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Solute Carrier Family 12 Member 2 overview
Solute Carrier Family 12 Member 2 (SLC12A2) plays a important role in the regulation of ionic balance and cell volume. SLC12A2 mediates the electroneutral transport of chloride, potassium and/or sodium ions across the membrane. Protein is phosphorylated in response to DNA damage. Three transcript variants encoding two different isoforms have been found..
For a complete picture of Solute Carrier Family 12 Member 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
